Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-TB is an innovative concept in TB treatment, aiming to develop a universal regimen effective for all forms of active TB, including both drug-susceptible and drug-resistant strains. The primary goal of the PAN-TB regimen is to simplify the treatment process, reduce costs, and improve treatment success rates. The ideal Target Regimen Profile (TRP) for PAN-TB includes superior efficacy compared to standard treatment for non-drug-resistant TB, a reduced treatment duration from the current 4-6 months to 2-3 months, and improved safety and tolerability. This project aims to explore a new ultra-short-course treatment regimen for both drug-sensitive (DS-TB) and drug-resistant TB (MDR/RR-TB), which aligns with the latest trends in TB treatment both domestically and internationally. The regimen also has significant practical implications for enhancing treatment efficacy and reducing patient burden. Furthermore, the study will explore the identification of new biomarkers closely linked to treatment outcomes over the course of full-cycle therapy.

Start Date15 Apr 2025

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University Sch of Med

NCT06917495

/ Not yet recruitingPhase 2IIT

Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical Trial

To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis.

Start Date05 Apr 2025

Sponsor / Collaborator

Shandong University

[+1]

NCT06253715

/ RecruitingPhase 3IIT

Shortened Regimen for Drug-susceptible TB in Children

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

Start Date15 Jan 2025

Sponsor / Collaborator

The Johns Hopkins University

100 Clinical Results associated with Pyrazinamide

100 Translational Medicine associated with Pyrazinamide

100 Patents (Medical) associated with Pyrazinamide

8,532

Literatures (Medical) associated with Pyrazinamide

31 Dec 2025·Emerging Microbes & Infections

The epidemiology and gene mutation characteristics of pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates in Southern China

Article

Author: Lai, Xiaomin ; Meng, Fanrong ; Chen, Yuanjin ; Hu, Jinxing ; Wei, Zeyou ; Niu, Qun ; Yang, Yu ; Wang, Nan ; Li, Hua ; Gong, Lan ; Wu, Ling ; Xie, Bei ; Gao, Junwen ; Wang, Qi ; Liu, Zhihui ; Deng, Li ; Lei, Jie ; Huang, Bo

This study investigates the epidemic trend of pyrazinamide (PZA)-resistant tuberculosis in Southern China over 11 years (2012-2022) and evaluates the mutation characteristics of PZA resistance-related genes (pncA, rpsA, and panD) in clinical Mycobacterium tuberculosis (M. tuberculosis) isolates. To fulfil these goals, we analyzed the phenotypic PZA resistance characteristics of 14,927 clinical isolates for which Bactec MGIT 960 PZA drug susceptibility testing (DST) results were available, revealing that 2,054 (13.76%) isolates were resistant to PZA. After evaluating the annual variation in the PZA resistance rate among tuberculosis cases in this region, it was observed that it decreased from 37.21% to 6.45% throughout the initial 7 years (2012-2018) and then increased from 8.01% to 12.12% over the subsequent 4 years (2019-2022). Sequences of pncA were obtained from 402 clinical M. tuberculosis complex isolates. For rpsA and panD, sequences were obtained from 360 clinical M. tuberculosis complex isolates. Mutations in pncA were found in 8 out of 223 PZA-sensitive isolates (3.59%) and 105 of 179 (58.66%) PZA-resistant isolates. Conversely, non-synonymous mutations in rpsA were identified in 5 of 137 (3.65%) PZA-resistant isolates, whereas the mutation ratio of rpsA among PZA-sensitive isolates was high at 14.03% (31/221). This difference in the rpsA mutation rate was statistically significant (P = 0.001, chi-square test). No panD mutations were observed in the 137 PZA-resistant isolates, whereas two PZA-sensitive isolates harboured point mutations in panD, including one nonsense mutation (C433 T) and another C-69 T mutation. These findings indicate that rpsA and panD may not significantly contribute to the development of PZA resistance in clinical M. tuberculosis isolates.

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

A Novel Monoallelic Small Deletion Confers Gain-of-Function of STAT1 in a Child with Candidiasis and Mycobacterial Diseases

Letter

Author: Galicia, Lizbeth Blancas ; Galicia, Lizbeth Blancas ; Blanco, Uriel Pérez ; STAT1 Consortium ; Okada, Satoshi ; Padilla, Sara Espinosa ; Bustamante, Jacinta ; Sanchez-Flores, Carlos ; Téllez, Virginia Lora ; Okada, Satoshi ; Tello, Héctor Gómez ; Tello, Hector Gomez ; Tsumura, Miyuki ; Tellez, Virginia Lora

01 Sep 2025·MICROBIAL PATHOGENESIS

Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress

Review

Author: Liu, Guihua ; Wang, Ying ; Cao, Daxing

Treatment regimens for Tuberculosis (TB) primarily rely on first-line drugs such as isoniazid, rifampicin, ethambutol, and pyrazinamide. Although these drugs have been pivotal in the treatment of drug-resistant tuberculosis, their high costs limit widespread use in low- and middle-income countries. However, the emergence of multidrug-resistant TB and extensively drug-resistant TB necessitates the development of new anti-TB drugs and therapeutic strategies. In terms of treatment, new drugs such as bedaquiline, delamanid, and pretomanid have shown significant efficacy against MDR-TB and XDR-TB. Combination therapies have substantially improved cure rates and reduced treatment duration. Despite these advancements, drug resistance and adverse effects remain substantial challenges. Understanding the resistant genes and biochemical mechanisms of M. tuberculosis, developing drugs that disrupt its biofilms, optimizing drug combinations, and personalizing treatments are crucial for reducing tuberculosis mortality and controlling its spread, thus achieving WHO's goal of global tuberculosis eradication. Future research should focus on improving drug accessibility and affordability, and making significantly contributions to global public health goals.

News (Medical) associated with Pyrazinamide

06 Feb 2025

·www.drugs.com

Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB

THURSDAY, Feb. 6, 2025 -- Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin -resistant tuberculosis , according to a study published in the Jan. 30 issue of the New England Journal of Medicine . Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points. The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar. "The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis," the authors write. Two authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3Clinical Result

28 Jan 2025

·www.drugs.com

Kansas Reports Largest Tuberculosis Outbreak in U.S. History

TUESDAY, Jan. 28, 2025 -- Kansas health officials are fighting the largest tuberculosis (TB) outbreak in U.S. history, with 67 confirmed cases since new year began. The outbreak includes 60 active cases in Wyandotte County and seven in Johnson County, according to the Kansas Department of Health and Environment (KDHE). That's the most since the 1950s, when the U.S. Centers for Disease Control and Prevention (CDC) began monitoring and reporting TB cases. Health officials are testing and treating affected individuals. "While there is a very low risk of infection to the general public in these communities, KDHE is working to ensure that patients are receiving appropriate treatment, which will limit the ability to spread this disease and prevent additional cases from occurring," KDHE spokeswoman Jill Bronaugh told the University of Minnesota's CIDRAP News in an email. "This outbreak is still ongoing, which means that there could be more cases." TB is caused by a bacterium called Mycobacterium tuberculosis, according to the CDC. It spreads through the air when someone with active TB disease coughs or speaks. People who spend time in close contact with someone who has active TB are at greatest risk of infection. TB typically affects the lungs but can also harm the brain, kidneys or spine. Here are the two forms : Kansas health officials are regularly screening anyone who tests positive to determine whether they have latent TB infection or active TB. Treatment for latent TB typically involves one or more medications, such as isoniazid or rifampin , for up to nine months. Active TB typically requires a longer treatment course with combinations of drugs, including ethambutol , rifampin and pyrazinamide . Although a TB vaccine exists (Bacille Calmette-Guérin), it is not commonly used in the U.S., the CDC said. Certain groups face a higher risk of TB , including people who: Local health departments in Kansas are conducting free testing for individuals, regardless of insurance coverage. SOURCES: Kansas Department of Health and Environment (KDHE), news release, Jan. 24, 2025; University of Minnesota CIDRAP News, news release, Jan. 27, 2025, USA Today , media report, Jan. 27, 2025 If you live in Kansas, especially in Wyandotte or Johnson County, consider getting tested for TB if you are at risk or have symptoms. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

VaccineClinical Study

01 Nov 2024

·www.tballiance.org

Introducing BPaL: Experiences from countries supported under the LIFT-TB project

11/2024 - PLoS One Author(s): D. F. Wares ,M. Mbenga ,V. Mirtskhulava ,M. Quelapio ,A. Slyzkyi ,I. Koppelaar ,S. N. Cho ,U. Go ,J. S. Lee ,J.-K. Jung ,D. Everitt ,S. Foraida ,M. Diachenko ,S. Juneja ,E. Burhan ,A. Totkogonova ,Z. Myint ,I. Flores ,N. A. Lytvynenko ,N. Parpieva ,N. V. Tags: BPaL, MDR-TB, Regimen Change 10/2024 Author(s): Denise Evans, Kamban Hirasen, Clive Ramushu, Lawrence Long, Edina Sinanovic, Francesca Conradie, Pauline Howell, Xavier Padanilam, Hannetjie Ferreira, Ebrahim Variaiva, Shakira Rajaram, Aastha Gupta, Sandeep Juneja, Norbert Ndjeka Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Drug Market, TB Market 8/2024 - IJTLD Open Author(s): C. Auer, A. Gupta, C. Malbacius, A. Ghafoor, Y. Kock, O. Medvedieva, P. Hanlon, P. Steinmann, and S. Juneja Tags: BPaL, MDR-TB, TB Drug Market, TB Market 7/2024 - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Author(s): B. Myrzaliev, M. Ahmatov, A. Duishekeeva, A. Kulzhabaeva, A. Kadyrov, A. Toktogonova, G. Abdulaeva, D.F. Wares , V. Mirtskhulava, M. Mbenga, A. Slyzkyi, S. Foraida, M. Diachenko, S. Juneja, G. Turdumambetova, A. Musaeva, A. Gebha Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Regimen Change, XDR-TB 6/2024 - The International Journal of Tuberculosis and Lung Disease Author(s): D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, Regimen Change, TB Drug Market 5/2024 - Lancet Infectious Diseases Author(s): Muge Cevik, MD Lindsay C Thompson, MPhil Caryn Upton, MD Valéria Cavalcanti Rolla Mookho Malahleha, MD Blandina Mmbaga, PhD Nosipho Ngubane, MD Zamzurina Abu Bakar, MD Mohammed Rassool, MD Ebrahim Variava, MD Rodney Dawson, MD Suzanne Staples, DPhil Umes Tags: Clinical Development, Clinical Trial Results, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide 5/2024 - Annals of Clinical Micobiology and Antimicrobials Author(s): Bing Zhao, Huiwen Zheng, Juliano Timm, Zexuan Song, Shaojun Pei, Ruida Xing, Yajie Guo, Ling Ma, Feina Li, Qing Li, Yan Li, Lin Huang, Chong Teng, Ni Wang, Aastha Gupta, Sandeep Juneja, Fei Huang, Yanlin Zhao, Xichao Ou Tags: Drug-Sensitivity Testing, M.tb. Biology, MDR-TB, Pretomanid/PA-824, XDR-TB 1/2024 - PLOS One Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market 11/2023 - International Journal of Tuberculosis and Lung Disease Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Hesseling, A. C., Garcia-Prats, A. J., Inabathina, K. Rao Tags: BENEFIT Kids, Underserved Populations 10/2023 - Clinical and Translational Science Author(s): Paloma Moraga, Paula Prieto, Almari Conradie, Majda Benhayoun, Vicki Rousell, Maria Davy, Uwe Fuhr, Rosa Antonijoan Arbos, Francisco Abad‐Santos, Antonio Portolés, Jolanda Van Duinen, Antonio J. Carcas, Alberto M. Borobia, and the ERA4TB Consortium Tags: Pharmacodynamics, Pharmacokinetics 10/2023 - Clinical Infectious Diseases Author(s): Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta, Linh Nguyen, Samuel Schumacher, Tim Schlub, Greg Fox Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824 10/2023 - PLOS Global Public Health Author(s): Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824 9/2023 - International Journal of Tuberculosis and Lung Disease Author(s): Viljoen, L., Acaba, J., Agbassi, Y. J. P., Beko, B., Goslett, C., Hoddinott, G., Kumar, B., Kumar, R. G., McKenna, L., Moses, G., Sachs, T., Seidel, S., von Delft, A. Tags: Advocacy, BENEFIT Kids, Underserved Populations 6/2023 - Indian Journal of Tuberculosis Author(s): Nibedita Rath, Chaitali Nikam, Stephanie Seidel, Anindya Sinha, Vijay Arora Tags: Advocacy, Community Engagement, TB Burden, Underserved Populations 5/2023 - Molecular Pharmaceutics Author(s): Hanh Thuy Nguyen, Tu Van Duong, Sarah Jaw-Tsai, Rebecca Bruning-Barry, Poonam Pande, Rajneesh Taneja, and Lynne S. Taylor Tags: Pretomanid/PA-824, TB Drug Market, Underserved Populations 3/2023 - International Journal of Tuberculosis and Lung Disease Author(s): R Taneja, M C Nahata, J Scarim, P G Pande, A Scarim, G Hoddinott, C L Fourie, R K Jew, H S Schaaf, A J Garcia-Prats, A C Hesseling Tags: Bedaquiline (TMC-207), BENEFIT Kids, Childhood TB, TB Burden, TB Market, Underserved Populations 3/2023 - Antimicrobial Agents and Chemotherapy Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824 3/2023 - International Journal of Infectious Diseases Author(s): Francesca Saluzzo, Juan Espinosa-Pereiro, Stephan Dressler, Ezio Tàvora Dos Santos Filho, Stephanie Seidel, Jesus Gonzalez Moreno, Norbert Heinrich, Adrian Sanchez-Montalva, Daniela Maria Cirillo Tags: Advocacy, Clinical Development, Community Engagement, Trial Design, Underserved Populations 2/2023 - International Journal of Tuberculosis and Lung Disease Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Hesseling, A. C., Garcia-Prats, A. J. Tags: BENEFIT Kids, Childhood TB, Clofazamine, Underserved Populations 1/2023 - Journal of Biopharmaceutical Statistics Author(s): James Buchanana, Mengchun Lib, Barbara Hendricksonc, Parul Bhargavad, Satrajit Roychoudhury Tags: Trial Design

100 Deals associated with Pyrazinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00144	Pyrazinamide	J04AK01	DB00339

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tuberculosis	Japan	Alfresa Pharma Corp.	20 Sep 1956

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02619994 (MDR-END, CTgov)	Phase 2	Tuberculosis, Multidrug-Resistant	214	Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm)	lcbewlyaen = reithovhtc vuhealonkr (iegrvazwsz, eqvegelocq - xkrrrmbifw) View more	-	03 Jan 2025
				levofloxacin+Linezolid+Delamanid+Pyrazinamide (Experimental Arm)	lcbewlyaen = ytnrjopmyf vuhealonkr (iegrvazwsz, spdbnnxkvm - gffbkztbht) View more
NCT03338621 (SimpliciTB, Pubmed \| Lancet Infect Dis)	Phase 2	Pulmonary Tuberculosis	455	Bedaquiline-pretomanid-moxifloxacin-pyrazinamide (BPaMZ) 4 months	nomzqwnldh(ygrjcsugbm) = three participants [1%] hhwniccaxa (wsinolwgil ) View more	Positive	01 Sep 2024
NCT03882177 (StAT-TB, CTgov)	Phase 2	Pulmonary Tuberculosis	16	Pravastatin+Vitamin B6+Rifafour (Arm 1: Pravastatin (40 mg) and Rifafour)	xtgvteiysw = ismwqnmhgg qcwxeupvnj (vkvovlqzzd, zufwkvxpkr - ionvpxpean) View more	-	18 Sep 2023
				Pravastatin+Vitamin B6+Rifafour (Arm 2: Pravastatin (80 mg) and Rifafour)	xtgvteiysw = vndnhnzhev qcwxeupvnj (vkvovlqzzd, soejlvudea - opkuxkkkrk) View more
NCT02256696 (CTgov)	Phase 2	Pulmonary Tuberculosis	157	PA-824+Rifampin+Isoniazid+Pyrazinamide (Arm 1)	hqxyvnrces(vuigdsutib) = fmfwlstdpf knnmlyllkd (mhovbcrnaf, mmuufykvym - tbervmxgbu) View more	-	18 Jul 2023
				PA-824+Rifabutin+Isoniazid+Pyrazinamide (Arm 2)	hqxyvnrces(vuigdsutib) = rjnafysdbh knnmlyllkd (mhovbcrnaf, pymjcqimzy - oomhzwtrik) View more
NCT02554318 (FSS, CTgov)	Not Applicable	Pulmonary Tuberculosis	147	Fermented soybean+Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Intervention)	upcgzipdij(idudwopvqs) = mrzsnauuzq wjcvsonzmm (chhejjazpt, 2.33) View more	-	21 Jun 2022
				Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Control)	upcgzipdij(idudwopvqs) = aehjbmrpqe wjcvsonzmm (chhejjazpt, 2.42) View more
NCT01601626 (CTgov)	Phase 2	Tuberculosis \| HIV Infections \| Tuberculosis, extrapulmonary	71	Ethambutol+Rifabutin+Pyridoxine+Standard-dose Lopinavir/Ritonavir+Isoniazid+Pyrazinamide (A: Standard-dose LPV/r w/RBT)	piofdhwmry = lccghwrtbl mojhnzoouo (wcxsthcetd, vpwhtmmbfx - blvuclyubu) View more	-	13 Feb 2018
				Ethambutol+Rifampin+Pyridoxine+Double-dose Lopinavir/Ritonavir+Isoniazid+Pyrazinamide (B: Double-dose LPV/r w/RIF)	piofdhwmry = dvnaqeeill mojhnzoouo (wcxsthcetd, jeympueluj - pezqmkjtaz) View more
NCT00864383 (REMoxTB, CTgov)	Phase 3	Pulmonary Tuberculosis	1,931	Ethambutol+Rifampicin+Moxifloxacin+Isoniazid+Pyrazinamide (Regimen 1 - 2EHRZ/4HR (Control Regimen))	bcxvsxxdcs = albdljkgkt ejnrnistws (imkbhuvpzu, twaphsgtsc - pqfymrnlsl) View more	-	25 May 2015
				Ethambutol+Rifampicin+Moxifloxacin+Isoniazid+Pyrazinamide (Regimen 2 - 2MHRZ/2MHR)	bcxvsxxdcs = uusmxylspe ejnrnistws (imkbhuvpzu, oifgoatmmr - tbzhcconwz) View more
NCT00130247 (CTgov)	Phase 3	Pulmonary Tuberculosis	394	ethambutol+rifampicin+INH+pyrazinamide (4-Month Arm)	jypmezwgue = leriyvnrjv mrxaywmbgy (itykmazqdb, dooxnxnbsg - qrklfujwce) View more	-	27 Jan 2010
				ethambutol+rifampicin+INH+pyrazinamide (6-Month Arm)	jypmezwgue = sgfmvenhda mrxaywmbgy (itykmazqdb, smutjidnpi - tdklgzbkat) View more
Pubmed \| Enferm Infecc Microbiol Clin	Not Applicable	anergy	319	Isoniazid for six months (6H)	bpuotdoalu(xekitsdftl) = oxljjzmqmz hvasrkejvb (ifhgceehlm )	Negative	01 Jan 2003
				Rifampin plus isoniazid for three months (3RH)	bpuotdoalu(xekitsdftl) = ypupdohrhm hvasrkejvb (ifhgceehlm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis